Temat: "MYELOPROLIFERATIVE disorders" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
Autorzy:: Giraldo-Rincón AI; Universidad de Antioquia, Facultad de Medicina, Unidad de Genética Médica, Medellín, Colombia.
Naranjo Molina S; Universidad de Antioquia, Facultad de Medicina, Unidad de Genética Médica, Medellín, Colombia.
Gomez-Lopera N; Universidad de Antioquia, Facultad de Medicina, Unidad de Genética Médica, Medellín, Colombia.
Aguirre Acevedo D; Universidad de Antioquia, Grupo Académico de Epidemiología Clinica, Medellin, Colombia.
Ucroz Benavidez A; Universidad de Antioquia, Facultad de Medicina, Unidad de Genética Médica, Medellín, Colombia.
Gálvez Cárdenas K; Hospital Pablo Tobón Uribe, Medellín, Colombia.
Cuellar Ambrosí F; Hospital Alma Mater, Medellín, Colombia.
Torres JD; Hospital Universitario San Vicente Fundación, Medellín, Colombia.
Ospina S; Hospital Universitario San Vicente Fundación, Medellín, Colombia.
Palacio K; Universidad de Antioquia, Facultad de Medicina, Unidad de Genética Médica, Medellín, Colombia.
Gaviria Jaramillo L; Hospital Universitario San Vicente Fundación, Medellín, Colombia.
Muñeton CM; Universidad de Antioquia, Facultad de Medicina, Unidad de Genética Médica, Medellín, Colombia.
Vasquez Palacio G; Universidad de Antioquia, Facultad de Medicina, Unidad de Genética Médica, Medellín, Colombia.; Pokaż więcej
Źródło:: Colombia medica (Cali, Colombia) [Colomb Med (Cali)] 2023 Sep 30; Vol. 54 (3), pp. e2035353. Date of Electronic Publication: 2023 Sep 30 (Print Publication: 2023).
Typ publikacji:: Journal Article
MeSH Terms:: Janus Kinase 2*/genetics
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/metabolism
Receptors, Thrombopoietin*/genetics
Calreticulin*/genetics
Humans ; Colombia ; Mutation ; Polycythemia Vera/genetics ; Primary Myelofibrosis/genetics ; Thrombocythemia, Essential/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.
Autorzy:: Lilleskare S; Department of Medicine, Stavanger University Hospital, Stavanger, Norway.
Vorland M; Department of Cancer Genomics, Haukeland University Hospital, Bergen, Norway.
Vo AK; Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Aarsand AK; Norwegian Porphyria Centre and Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.; Norwegian Organization for Quality Improvement of Laboratory Examinations, Haraldsplass Deaconess Hospital, Bergen, Norway.
Reikvam H; Department of Medicine, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.; Pokaż więcej
Źródło:: Scandinavian journal of clinical and laboratory investigation [Scand J Clin Lab Invest] 2023 Feb; Vol. 83 (1), pp. 3-7. Date of Electronic Publication: 2022 Dec 07.
Typ publikacji:: Journal Article
MeSH Terms:: Janus Kinase 2*/genetics
Janus Kinase 2*/metabolism
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/genetics
Receptors, Thrombopoietin*/genetics
Receptors, Thrombopoietin*/metabolism
Calreticulin*/metabolism
Humans ; Hemoglobins ; Mutation ; Polycythemia Vera/genetics ; Primary Myelofibrosis/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.
Autorzy:: Aswad MH; Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Kissova J; Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Ovesna P; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Říhová L; Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Penka M; Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Pokaż więcej
Źródło:: Clinical hemorheology and microcirculation [Clin Hemorheol Microcirc] 2023; Vol. 84 (4), pp. 359-368.
Typ publikacji:: Journal Article
MeSH Terms:: Janus Kinase 2*/genetics
Myeloproliferative Disorders*/complications
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/pathology
Thrombocythemia, Essential*/genetics
Thrombocythemia, Essential*/complications
Thrombocythemia, Essential*/pathology
Thrombosis*/genetics
Thrombosis*/pathology
Humans ; Blood Platelets ; Mutation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.
Autorzy:: Ngoc NT; Department of Life Sciences, University of Science and Technology of Hanoi, Vietnam Academy of Science and Technology, Hanoi, Vietnam.
Hau BB; Department of Life Sciences, University of Science and Technology of Hanoi, Vietnam Academy of Science and Technology, Hanoi, Vietnam.
Vuong NB; 103 Hospital, Vietnam Military Medical University, Hanoi, Vietnam.
Xuan NT; Vietnam Academy of Science and Technology, Institute of Genome Research, Hanoi, Vietnam.; Pokaż więcej
Źródło:: Molecular genetics & genomic medicine [Mol Genet Genomic Med] 2022 Oct; Vol. 10 (10), pp. e2044. Date of Electronic Publication: 2022 Aug 22.
Typ publikacji:: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms:: Janus Kinase 2*/genetics
Myeloproliferative Disorders*/genetics
Polycythemia Vera*/genetics
Primary Myelofibrosis*/genetics
Thrombocythemia, Essential*/genetics
Asian People ; DNA ; Genetic Markers ; Humans ; Vietnam

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
Autorzy:: Zhao Y; From the Department of Pathology, College of Basic Medical Sciences and First Affiliated Hospital, China Medical University, Shenyang, China (Zhao).; From the Department of Pathology, Duke University School of Medicine, Durham, North Carolina (Zhao, McCracken, Iranzad, Rehder, Neff, Wang).
Reddi D; From the Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle (Reddi).
McCracken J; From the Department of Pathology, Duke University School of Medicine, Durham, North Carolina (Zhao, McCracken, Iranzad, Rehder, Neff, Wang).
Iranzad N; From the Department of Pathology, Duke University School of Medicine, Durham, North Carolina (Zhao, McCracken, Iranzad, Rehder, Neff, Wang).
Rehder C; From the Department of Pathology, Duke University School of Medicine, Durham, North Carolina (Zhao, McCracken, Iranzad, Rehder, Neff, Wang).
Neff J; From the Department of Pathology, Duke University School of Medicine, Durham, North Carolina (Zhao, McCracken, Iranzad, Rehder, Neff, Wang).
Wang E; From the Department of Pathology, Duke University School of Medicine, Durham, North Carolina (Zhao, McCracken, Iranzad, Rehder, Neff, Wang).; Pokaż więcej
Źródło:: Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2022 Jun 01; Vol. 146 (6), pp. 710-717.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/pathology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/therapy
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/therapy
Fusion Proteins, bcr-abl/*genetics
Janus Kinase 2/*genetics
Fusion Proteins, bcr-abl/metabolism ; Humans ; Hydroxyurea/therapeutic use ; Janus Kinase 2/metabolism ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2 cells.
Autorzy:: Zhou J; Tongji University School of Medicine, Shanghai, 200092, China.; Department of Gastroenterology, Tongji Hospital of Tongji University, Shanghai, 200065, China.
Guo C; Tongji University School of Medicine, Shanghai, 200092, China.; Department of Gastroenterology, Tongji Hospital of Tongji University, Shanghai, 200065, China.
Wu H; Tongji University School of Medicine, Shanghai, 200092, China.; Department of Hematology, Tongji Hospital of Tongji University, Tongji University School of Medicine, No.389 Xincun Road, Putuo District, Shanghai, 200065, China.
Li B; Tongji University School of Medicine, Shanghai, 200092, China.; Department of Hematology, Tongji Hospital of Tongji University, Tongji University School of Medicine, No.389 Xincun Road, Putuo District, Shanghai, 200065, China.
Zhou LL; Tongji University School of Medicine, Shanghai, 200092, China.; Department of Hematology, Tongji Hospital of Tongji University, Tongji University School of Medicine, No.389 Xincun Road, Putuo District, Shanghai, 200065, China.
Liang AB; Tongji University School of Medicine, Shanghai, 200092, China. .; Department of Hematology, Tongji Hospital of Tongji University, Tongji University School of Medicine, No.389 Xincun Road, Putuo District, Shanghai, 200065, China. .
Fu JF; Tongji University School of Medicine, Shanghai, 200092, China. .; Department of Hematology, Tongji Hospital of Tongji University, Tongji University School of Medicine, No.389 Xincun Road, Putuo District, Shanghai, 200065, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Nov 13; Vol. 21 (1), pp. 1213. Date of Electronic Publication: 2021 Nov 13.
Typ publikacji:: Journal Article
MeSH Terms:: Cyclin-Dependent Kinase Inhibitor p21/*metabolism
DNA Methyltransferase 3A/*metabolism
Janus Kinase 2/*metabolism
MicroRNAs/*metabolism
Myeloproliferative Disorders/*metabolism
STAT5 Transcription Factor/*metabolism
Tumor Suppressor Proteins/*metabolism
Aminopyridines/pharmacology ; Animals ; Binding Sites ; Blotting, Western ; Case-Control Studies ; Cell Count ; Cell Line ; Cell Line, Tumor ; Cell Proliferation ; DNA Methyltransferase 3A/genetics ; Down-Regulation ; Exons ; G1 Phase Cell Cycle Checkpoints ; Humans ; Imidazoles/pharmacology ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase 2/genetics ; K562 Cells ; Mice ; Monocytes/metabolism ; Mutation ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/pathology ; Promoter Regions, Genetic ; Pyrazoles/pharmacology ; Pyridazines/pharmacology ; Signal Transduction ; Transcription, Genetic ; Tumor Stem Cell Assay ; U937 Cells

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.
Autorzy:: Gou P; Laboratoire UMRS-1131, Ecole doctorale 561, Université de Paris, 75010 Paris, France.; INSERM UMR-S1131, Hôpital Saint-Louis, 75010 Paris, France.
Zhang W; BFA, UMR 8251, CNRS, Université de Paris, 75013 Paris, France.
Giraudier S; Laboratoire UMRS-1131, Ecole doctorale 561, Université de Paris, 75010 Paris, France.; INSERM UMR-S1131, Hôpital Saint-Louis, 75010 Paris, France.; Service de Biologie Cellulaire, Hôpital Saint-Louis, AP-HP, 75010 Paris, France.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Jan 18; Vol. 23 (3). Date of Electronic Publication: 2022 Jan 18.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Amino Acid Substitution*
Janus Kinase 2/*metabolism
Myeloproliferative Disorders/*pathology
Epigenesis, Genetic ; Humans ; Janus Kinase 2/chemistry ; Janus Kinase 2/genetics ; MAP Kinase Signaling System ; Models, Molecular ; Myeloproliferative Disorders/genetics ; Protein Domains

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.
Autorzy:: Zheng CF; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zhao XX; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Chen XH; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Liu Z; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Wang WJ; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Luo M; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Ren Y; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Wang HW; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.; Pokaż więcej
Źródło:: International journal of laboratory hematology [Int J Lab Hematol] 2021 Aug; Vol. 43 (4), pp. 645-650. Date of Electronic Publication: 2021 May 11.
Typ publikacji:: Journal Article
MeSH Terms:: Hematologic Neoplasms*/diagnosis
Hematologic Neoplasms*/genetics
Mutation, Missense*
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/genetics
Polymerase Chain Reaction*
Janus Kinase 2/*genetics
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Amino Acid Substitution ; Female ; Humans ; Male ; Middle Aged

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Functional analysis of atypical mutations in exons 13 and 15 of JAK2 gene in myeloproliferative neoplasms.
Autorzy:: Luo M; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Tian T; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zhang Y; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zhang X; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Xie J; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Xu J; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Ren W; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Tian C; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Wang J; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Tan Y; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Wang H; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Chen X; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.; Pokaż więcej
Źródło:: International journal of laboratory hematology [Int J Lab Hematol] 2021 Jun; Vol. 43 (3), pp. e110-e113. Date of Electronic Publication: 2020 Nov 27.
Typ publikacji:: Letter
MeSH Terms:: Exons*
Mutation*
Janus Kinase 2/*genetics
Myeloproliferative Disorders/*diagnosis
Myeloproliferative Disorders/*genetics
Disease Management ; Disease Susceptibility ; Genetic Predisposition to Disease ; Genetic Testing ; Humans ; Janus Kinase 2/metabolism ; Myeloproliferative Disorders/metabolism

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.
Autorzy:: Stuckey R; Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas, Spain.
Gómez-Casares MT; Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas, Spain.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 May 10; Vol. 22 (9). Date of Electronic Publication: 2021 May 10.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Janus Kinase 2/*genetics
Myeloproliferative Disorders/*drug therapy
Polycythemia Vera/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Humans ; Janus Kinase 2/antagonists & inhibitors ; Mutation/genetics ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/pathology ; Polycythemia Vera/diagnosis ; Polycythemia Vera/genetics ; Polycythemia Vera/pathology ; Prognosis ; Thrombosis/drug therapy ; Thrombosis/genetics ; Thrombosis/pathology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
Autorzy:: Hekimoğlu H; İstanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, İstanbul, Turkey; Institute of Health Sciences, İstanbul University, İstanbul, Turkey
Toprak SF; İstanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, İstanbul, Turkey; Institute of Health Sciences, İstanbul University, İstanbul, Turkey
Sözer S; İstanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, İstanbul, Turkey; Pokaż więcej
Źródło:: Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2022 Feb 23; Vol. 39 (1), pp. 13-21. Date of Electronic Publication: 2022 Jan 04.
Typ publikacji:: Journal Article
MeSH Terms:: Apoptosis*
Cell-Derived Microparticles*/metabolism
Endothelial Cells*/enzymology
Janus Kinase 2*/genetics
Janus Kinase 2*/metabolism
Humans ; Mutation ; Myeloproliferative Disorders/genetics ; Thrombosis/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: A novel JAK2 R564* variant in a patient with thrombocytosis.
Autorzy:: Villanueva A; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Poon KS; Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Health System, Singapore.
Gallardo CA; Department of Haematology, Tan Tock Seng Hospital, National Healthcare Group, Singapore.
Chai CN; Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Health System, Singapore.
Chiu L; Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Health System, Singapore.
Yan B; Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Health System, Singapore.
Ding CSL; Department of Pathology, Tan Tock Seng Hospital, National Healthcare Group, Singapore.
Yong KJ; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Zhou J; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Lee J; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.
Tan K; Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Health System, Singapore.
Ong KH; Department of Haematology, Tan Tock Seng Hospital, National Healthcare Group, Singapore.; Pokaż więcej
Źródło:: International journal of laboratory hematology [Int J Lab Hematol] 2020 Apr; Vol. 42 (2), pp. e38-e41. Date of Electronic Publication: 2019 Aug 23.
Typ publikacji:: Case Reports; Letter
MeSH Terms:: Mutation*
Janus Kinase 2/*genetics
Myeloproliferative Disorders/*genetics
Thrombocytosis/*genetics
Clopidogrel/therapeutic use ; Female ; Humans ; Janus Kinase 2/metabolism ; Middle Aged ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/drug therapy ; Platelet Aggregation Inhibitors/therapeutic use

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Autorzy:: Belcic Mikic T; Department of Haematology, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia. .; Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000, Ljubljana, Slovenia. .
Pajic T; Department of Haematology, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia.; Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000, Maribor, Slovenia.
Sever M; Department of Haematology, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000, Ljubljana, Slovenia.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2019 Dec 27; Vol. 9 (1), pp. 19838. Date of Electronic Publication: 2019 Dec 27.
Typ publikacji:: Journal Article
MeSH Terms:: Mutation*
Calreticulin/*genetics
Janus Kinase 2/*genetics
Myeloproliferative Disorders/*genetics
Thrombocythemia, Essential/*genetics
Adult ; Calreticulin/classification ; Calreticulin/metabolism ; Cohort Studies ; DNA Mutational Analysis/methods ; Female ; Genetic Testing/methods ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/metabolism ; Humans ; Janus Kinase 2/metabolism ; Male ; Middle Aged ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/metabolism ; Reproducibility of Results ; Sensitivity and Specificity ; Thrombocythemia, Essential/diagnosis ; Thrombocythemia, Essential/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
Autorzy:: Chapeau EA; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Mandon E; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Gill J; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Romanet V; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Ebel N; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Powajbo V; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Andraos-Rey R; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Qian Z; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Kininis M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Zumstein-Mecker S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Ito M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Hynes NE; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Tiedt R; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Hofmann F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Eshkind L; Institute for Translational Immunology and Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Bockamp E; Institute for Translational Immunology and Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Kinzel B; Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Mueller M; Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Murakami M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Baffert F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Radimerski T; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2019 Oct 10; Vol. 14 (10), pp. e0221635. Date of Electronic Publication: 2019 Oct 10 (Print Publication: 2019).
Typ publikacji:: Journal Article
MeSH Terms:: Gene Expression Regulation*
Hematopoietic Stem Cells*/metabolism
Hematopoietic Stem Cells*/pathology
Janus Kinase 2*/biosynthesis
Janus Kinase 2*/genetics
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/metabolism
Myeloproliferative Disorders*/pathology
Transgenes*
Amino Acid Substitution ; Animals ; Disease Models, Animal ; Humans ; Mice ; Mice, Transgenic ; Mutation, Missense

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Reversine exhibits antineoplastic activity in JAK2 -positive myeloproliferative neoplasms.
Autorzy:: Lima K; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Carlos JAEG; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Alves-Paiva RM; Einstein's Teaching and Research Institute, Albert Einstein Hospital, São Paulo, Brazil.
Vicari HP; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Souza Santos FP; Einstein's Teaching and Research Institute, Albert Einstein Hospital, São Paulo, Brazil.
Hamerschlak N; Einstein's Teaching and Research Institute, Albert Einstein Hospital, São Paulo, Brazil.
Costa-Lotufo LV; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Traina F; Department of Medical Images, Hematology and Clinical Oncology, University of São Paulo at Ribeirão Preto Medical School, Ribeirão Preto, São Paulo, Brazil.
Machado-Neto JA; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2019 Jul 09; Vol. 9 (1), pp. 9895. Date of Electronic Publication: 2019 Jul 09.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Apoptosis*
Mutation*
Biomarkers, Tumor/*metabolism
Gene Expression Regulation, Neoplastic/*drug effects
Janus Kinase 2/*metabolism
Morpholines/*pharmacology
Myeloproliferative Disorders/*pathology
Purines/*pharmacology
Aurora Kinase A/genetics ; Aurora Kinase A/metabolism ; Aurora Kinase B/genetics ; Aurora Kinase B/metabolism ; Biomarkers, Tumor/genetics ; Cell Cycle ; Cell Proliferation ; Humans ; Janus Kinase 2/genetics ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/metabolism ; Protein Kinase Inhibitors ; Tumor Cells, Cultured

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Autorzy:: Sapre M; Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Tremblay D; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Wilck E; Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
James A; Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Leiter A; Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Coltoff A; Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Koshy AG; Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Kremyanskaya M; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Hoffman R; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Mascarenhas JO; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Gallagher EJ; Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. .; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2019 Nov 12; Vol. 9 (1), pp. 16609. Date of Electronic Publication: 2019 Nov 12.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Bone Marrow Neoplasms/*drug therapy
Janus Kinase 1/*antagonists & inhibitors
Janus Kinase 2/*antagonists & inhibitors
Myeloproliferative Disorders/*drug therapy
Pyrazoles/*therapeutic use
Adipose Tissue/drug effects ; Adipose Tissue/enzymology ; Adipose Tissue/metabolism ; Adult ; Aged ; Aged, 80 and over ; Animals ; Blotting, Western ; Body Mass Index ; Body Weight/drug effects ; Bone Marrow Neoplasms/metabolism ; Disease Models, Animal ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Myeloproliferative Disorders/metabolism ; Nitriles ; Pyrimidines ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
Autorzy:: Nilsri N; Doctor of Philosophy Program in Medical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Department of Medical Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok, Thailand.
Jangprasert P; Interdisciplinary Program of Biomedical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Pawinwongchai J; Faculty of Medical Technology, Rangsit University, Pathum Thani, Thailand.
Israsena N; Stem Cell and Cell Therapy Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Rojnuckarin P; Research Unit in Translational Hematology, Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Mar 04; Vol. 11 (1), pp. 5255. Date of Electronic Publication: 2021 Mar 04.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Janus Kinase 2/*genetics
Polycythemia/*genetics
Polycythemia Vera/*genetics
STAT1 Transcription Factor/*genetics
STAT3 Transcription Factor/*genetics
Erythropoiesis/genetics ; Exons ; Gene Expression Regulation/genetics ; Humans ; Induced Pluripotent Stem Cells/metabolism ; Mutation/genetics ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/pathology ; Polycythemia/pathology ; Polycythemia Vera/pathology ; Primary Myelofibrosis ; STAT Transcription Factors/genetics ; Thrombocythemia, Essential/genetics ; Thrombocythemia, Essential/pathology ; Thrombocytosis/genetics ; Thrombocytosis/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2 against myeloproliferative neoplasms.
Autorzy:: Hu M; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Xu C; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Yang C; Department of Blood Transfusion, General Hospital of the PLA Rocket Force, Beijing, 100088, China.
Zuo H; Department of Hematology, 307 Hospital of the PLA, Beijing, 100071, China.
Chen C; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Zhang D; Department of Pharmacy, China-Japan Friendship Hospital, Beijing, 100029, China.
Shi G; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Wang W; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Shi J; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Zhang T; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. .; School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China. .; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2019 Feb 04; Vol. 38 (1), pp. 49. Date of Electronic Publication: 2019 Feb 04.
Typ publikacji:: Journal Article
MeSH Terms:: Drugs, Chinese Herbal/*therapeutic use
Janus Kinase 2/*antagonists & inhibitors
Myeloproliferative Disorders/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Animals ; Apoptosis/drug effects ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drugs, Chinese Herbal/administration & dosage ; Drugs, Chinese Herbal/pharmacology ; Female ; Humans ; Isatis/chemistry ; Janus Kinase 2/blood ; Janus Kinase 2/genetics ; Male ; Mice ; Mice, Nude ; Myeloproliferative Disorders/blood ; Myeloproliferative Disorders/genetics ; Neoplastic Stem Cells/drug effects ; Point Mutation ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacology ; STAT3 Transcription Factor/metabolism ; STAT5 Transcription Factor/metabolism ; Xenograft Model Antitumor Assays

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.
Autorzy:: Gerlach MM; a Institute of Pathology , University Hospital Basel , Basel , Switzerland.
Lundberg P; b Department for Hematology , University Hospital Basel , Basel , Switzerland.
Halter J; b Department for Hematology , University Hospital Basel , Basel , Switzerland.
Arranto C; b Department for Hematology , University Hospital Basel , Basel , Switzerland.
Wenzel F; c Institute of Medical Genetics , University Hospital Basel , Basel , Switzerland.
Dirnhofer S; a Institute of Pathology , University Hospital Basel , Basel , Switzerland.
Tzankov A; a Institute of Pathology , University Hospital Basel , Basel , Switzerland.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2018 Aug; Vol. 59 (8), pp. 1994-1997. Date of Electronic Publication: 2017 Dec 03.
Typ publikacji:: Case Reports; Letter
MeSH Terms:: Mutation*
DNA-Binding Proteins/*genetics
Janus Kinase 2/*genetics
Myeloproliferative Disorders/*genetics
Proto-Oncogene Proteins/*genetics
Receptors, Colony-Stimulating Factor/*genetics
Splicing Factor U2AF/*genetics
Aged ; Dioxygenases ; Humans ; Male ; Myeloproliferative Disorders/drug therapy ; Myeloproliferative Disorders/pathology ; Nitriles ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/therapeutic use ; Pyrimidines

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Concomitant presence of JAK2V617F mutation and BCR‑ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report).
Autorzy:: Mousinho F; Department of Clinical Hematology, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal.
Azevedo AP; Department of Clinical Pathology, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal.
Mendes T; Department of Clinical Hematology, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal.
Santos PSE; Department of Clinical Hematology, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal.
Cerqueira R; CGC Clinical Genetics Centre, 4000‑432 Porto, Portugal.
Matos S; GenoMed‑Molecular Medicine Diagnosis, Molecular Medicine Institute, Faculty of Medicine University of Lisbon, 1649‑028 Lisbon, Portugal.
Santos S; GenoMed‑Molecular Medicine Diagnosis, Molecular Medicine Institute, Faculty of Medicine University of Lisbon, 1649‑028 Lisbon, Portugal.
Ramos S; Pathology Department, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal.
Viana JF; Department of Clinical Pathology, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal.
Lima F; Department of Clinical Hematology, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal.; Pokaż więcej
Źródło:: Molecular medicine reports [Mol Med Rep] 2018 Jul; Vol. 18 (1), pp. 1001-1006. Date of Electronic Publication: 2018 May 17.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Fusion Proteins, bcr-abl*/genetics
Fusion Proteins, bcr-abl*/metabolism
Hematologic Neoplasms*/diagnosis
Hematologic Neoplasms*/genetics
Hematologic Neoplasms*/metabolism
Hematologic Neoplasms*/pathology
Janus Kinase 2*/genetics
Janus Kinase 2*/metabolism
Mutation, Missense*
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/metabolism
Myeloproliferative Disorders*/pathology
Translocation, Genetic*
Aged ; Amino Acid Substitution ; Humans ; Male

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""MYELOPROLIFERATIVE disorders"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język